Anti-Obesity Drug Development

Dr. Fadia S. Youssef is an Associate Professor at the Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, Egypt since 2019. She was graduated from Faculty of Pharmacy, Ain Shams University in 2004. She received her Masters and PhD degrees from Faculty of Pharmacy, Ain Shams University. She was awarded a post-doctoral fellowship at the Institute of Pharmaceutical Biology and Biotechnology at Heinrich Heine University, Düsseldorf, Germany in 2018. She received the National Encouragement Award offered by the Egyptian Government in 2019. Her current research interests include the isolation of secondary metabolites from natural products as plant species, marine organisms and its associated fungi as well as essential oils extraction and its biological evaluation. Recently, she has been listed among the world’s top 2% of most important scientists issued by Stanford University. Dr. Mohamed L. Ashour is a full professor of Pharmacognosy at Ain Shams University, Cairo Egypt since 2020. He was graduated at 1996 from Faculty of Pharmacy, Alexandria University and he obtained his Master degree in Pharmacognosy from Department of Pharmacognosy, Ain Shams University, Egypt. He got his PhD on 2010 from Department of Pharmaceutical Biology, Heidelberg University, Germany. His main research interest in medicinal plants with special emphasis on isolation, structure elucidation and biological screening of secondary metabolites from plants and marine organisms. In addition to application of molecular modelling and multivariate analysis in natural products research. He has international collaboration with Saudi Arabia, Germany, Tunisia, Italy, Algeria, Uzbekistan, Morocco, and China.

Part I – Foundations and historical development on Anti-Obesity Drugs
1. Introduction
2. Historical overview of drug development and therapeutics
3. Neuroendocrine consideration
4. Alternative therapies
5. Comorbidities and their impact on therapies
6. Challenges for anti-obesity drug development FDA approved versus non-conventional and non-drug therapy of obesity

Part II – Drug targets involved in progression and treatment of obesity
7. GLP1R and GIPR agonists
8. Incretin/Glucagon
9. RM-493 and Liraglutide
10. Pramlintide and metreleptin
11. Growth hormone
12. Farnesoid X receptor (FXR) and membrane bound bile acid receptor (GPR131)
13. Gut Microbiota Matrix metalloproteinase (MMPs) Drug delivery technologies

Part III - Drugs
14. Orlistat
15. Liraglutide
16. Lorcaserin
17. Semaglutide
18. Setmelanotide
19. Tirzepatide
20. Combination Therapies:
a. phentermine/topiramate
b. naltrexone/bupropion

Part IV – Natural Products
21. Chitosan
22. Chromium Picolinate
23. Conjugated Linoleic Acid (CLA)
24. Glucomannan
25. Green Tea Extract
26. Green Coffee Extract
27. Guar Gum
28. Hoodia
29. 7-Keto-DHEA
30. Ephedra
31. Bitter Orange